Business · 18/03/2026Updated: 10/16/2026 · 1 min read
FDA Renews Obstetrics, Reproductive and Urologic Drugs Advisory Committee for 2 Years
Summary
The FDA is renewing the Obstetrics, Reproductive and Urologic Drugs Advisory Committee for an additional 2 years, with a new charter set to expire on March 23, 2028.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →